Revisiting the initial diagnosis and blood staging of mycosis fungoides and Sézary syndrome with the KIR3DL2 marker.

Date publication

juin 2020

Journal

The British journal of dermatology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BENSUSSAN Armand

Tous les auteurs :
Roelens M, de Masson A, Ram-Wolff C, Maki G, Cayuela JM, Marie-Cardine A, Bensussan A, Toubert A, Bagot M, Moins-Teisserenc H

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/31487384

Résumé

The early diagnosis of Sézary syndrome (SS) is challenging. Loss of CD7 and CD26 expression on CD4 T cells is the currently used criterion in the initial diagnosis and staging of patients with SS.

Mots clés

Humans, Mycosis Fungoides, diagnosis, Prospective Studies, Receptors, KIR3DL2, Reproducibility of Results, Sezary Syndrome, diagnosis, Skin Neoplasms, diagnosis

Référence

Br J Dermatol. 2020 06;182(6):1415-1422